Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies (Q32173424)

6 July 2017

1 reference

title

Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies (English)

1 reference

6 July 2017

A M Senderowicz

1

1 reference

6 July 2017

1 January 2001

1 reference

6 July 2017

1 reference

6 July 2017

15

1 reference

6 July 2017

1

1 reference

6 July 2017

1-9

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

6 July 2017

1 reference

7 January 2021

Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

The regulation of E2F by pRB-family proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

The role of RB in cell cycle control

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

The retinoblastoma protein and cell cycle control

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Cyclin-dependent kinases: engines, clocks, and microprocessors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Identification of multiple cyclin subunits of human P-TEFb

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

CDK inhibitors: positive and negative regulators of G1-phase progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Cyclins and cyclin-dependent kinases: theme and variations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Human T-cell leukemia virus type 1 Tax and cell cycle progression: role of cyclin D-cdk and p110Rb

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Mining the human proteome: experience with the human lymphoid protein database

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Preclinical and clinical development of cyclin-dependent kinase modulators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Inhibition of CDKs as a therapeutic modality.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Chemical inhibitors of cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

28 Use and specificity of staurosporine, UCN-O1, and calphostin C as protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

UCN-01, a selective inhibitor of protein kinase C from Streptomyces.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Cell cycle checkpoints: preventing an identity crisis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401994

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2401994

1 reference

PubMed ID

11243375

Dimensions Publication ID

6 July 2017

0 references

1 reference

PubMed ID

11243375